In a groundbreaking advancement poised to reshape cancer therapeutics, researchers at Dartmouth Cancer Center (DCC) have unveiled compelling evidence that telmisartan—a widely prescribed and FDA-approved blood pressure medication—dramatically enhances the effectiveness of olaparib, a leading PARP inhibitor widely used in targeted cancer treatments. Under the expert guidance of Dr. Tyler J. Curiel, MD, MPH, FACP, the team’s findings reveal the untapped potential of telmisartan to broaden the patient population benefitting from olaparib, a drug typically reserved for tumors exhibiting specific genetic vulnerabilities.
PARP inhibitors like olaparib operate by exploiting inherent defects in cancer cells’ DNA damage repair pathways, particularly homologous recombination deficiencies commonly seen in tumors harboring BRCA gene mutations. This approach disrupts the tumor’s ability to repair double-strand DNA breaks, leading to cell death. However, a significant limitation has been the narrow applicability of PARP inhibitors, as many tumors lack these DNA repair deficiencies, rendering them less responsive to such treatments. Additionally, resistance to PARP inhibitors frequently develops over time, further diminishing their clinical utility.
The Dartmouth team’s research directly confronts these challenges by demonstrating that telmisartan can sensitize tumors ordinarily resistant to olaparib, effectively extending the drug’s therapeutic reach. Intriguingly, preclinical models revealed that when telmisartan is combined with olaparib, there is a pronounced increase in tumor DNA damage accompanied by a robust modulation of the tumor immune microenvironment. Central to this immune effect is the augmented production of type I interferons—cytokines essential for initiating immune surveillance and recruiting immune effector cells to attack malignant tissues.
Mechanistically, the enhancement appears multifactorial. Beyond its canonical role as an angiotensin II receptor blocker (ARB), telmisartan uniquely influences cancer cell biology compared to other drugs within its class. Notably, the study highlights telmisartan’s capacity to downregulate PD-L1 expression within tumor cells, a critical immune checkpoint molecule tumors exploit to evade immune destruction. This downregulation potentially unleashes the immune system’s ability to recognize and eliminate cancer cells more effectively, synergizing with olaparib’s DNA-damaging effects.
These discoveries are particularly compelling given the longstanding safety profile, oral bioavailability, and tolerability of telmisartan, even among patients without hypertension. Such characteristics embolden its candidacy for rapid clinical translation, circumventing the extended timelines often associated with novel drug development. Embracing this prospect, Dr. Curiel and colleagues have already initiated two clinical trials deploying the combinatorial therapy in challenging cancer contexts: metastatic, castration-resistant prostate cancer and platinum-resistant ovarian cancer. Early patient responses are promising, underscoring the translational potential of this strategy.
Prostate cancer patients exhibiting resistance to conventional castration therapies face a dire need for new efficacious treatments. The incorporation of telmisartan with olaparib offers hope to surmount this barrier. Similarly, platinum-resistant ovarian cancer, notorious for poor therapeutic outcomes and aggressive progression, might greatly benefit from this refined approach. These trials not only explore tumor response but also interrogate the immunomodulatory effects elicited by telmisartan in a clinical setting.
Beyond the immediate implications for PARP inhibitor therapy, the Cornell team’s data extend the horizon to include enhancements in other oncological treatments, such as chemotherapy and immunotherapy. The underlying mechanisms—the modulation of immune signaling cascades and interference with tumor immune escape pathways—suggest a versatile role for telmisartan as an adjuvant agent. Its pleiotropic effects emphasize the importance of reexamining existing medications for novel applications within oncology, exemplifying the growing field of drug repurposing.
At the molecular level, the potentiation of type I interferon signaling by the telmisartan-olaparib combination constitutes a critical axis of this therapeutic synergy. Type I interferons orchestrate a complex network of immune responses that include activation of dendritic cells, cytotoxic T lymphocytes, and natural killer cells, all instrumental in mounting an effective antitumor response. This immunogenic cell death pathway facilitated by increased DNA damage profoundly alters the tumor microenvironment, rendering previously ‘cold’ tumors immunologically ‘hot’ and responsive.
The study’s unique positioning within the larger landscape of cancer research is underscored by its integrative approach to targeting tumor cells not only through direct cytotoxic DNA damage but also by manipulating the immune landscape to enhance antitumor efficacy. This dual-targeted strategy aligns with emerging paradigms in oncology that recognize the intricate interplay between tumor genetics and host immunity as critical determinants of therapeutic success.
Dr. Curiel’s research was made possible with the pivotal support of the Guyre and Gmelich funds at Dartmouth Cancer Center, illustrating the critical role of institutional backing in advancing translational cancer research. The Dartmouth Cancer Center itself, a prestigious National Cancer Institute-designated Comprehensive Cancer Center, continues to serve as a beacon for interdisciplinary innovation, leveraging partnerships with Dartmouth College and the Geisel School of Medicine, while delivering cutting-edge clinical care.
As the cancer research community eagerly monitors the outcomes of ongoing clinical trials, the potential repurposing of telmisartan as a cancer adjuvant represents a paradigm shift in oncological therapeutics. The implications for patient outcomes are profound: a safe, affordable, and accessible medication augmenting the efficacy of existing targeted therapies could revolutionize treatment algorithms across multiple cancer types, ultimately improving survival and quality of life for countless patients.
This next chapter in cancer therapy not only reflects the power of combining molecular precision with immunological engagement but also signals a critical move toward expanding treatment accessibility. Telmisartan’s repositioning exploits existing pharmacological knowledge, accelerating the journey from bench to bedside and embodying the future of personalized, multidisciplinary cancer care.
—
Subject of Research: Enhancement of PARP inhibitor efficacy in cancer using telmisartan
Article Title: Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production
News Publication Date: 25-Mar-2026
Web References: http://dx.doi.org/10.1136/jitc-2025-012426
References: Experimental study published in The Journal for ImmunoTherapy of Cancer
Keywords: Telmisartan, olaparib, PARP inhibitors, homologous recombination, type I interferons, cancer immunotherapy, tumor microenvironment, PD-L1, drug repurposing, metastatic prostate cancer, platinum-resistant ovarian cancer, angiotensin II receptor blockers
